Illumina company profile
Company profile
Illumina has 8,600 employees and is headquartered in San Diego, United States.
The Americas generate the largest share of revenue, 55.4% of the total in the fiscal year ended December 2025, followed by Europe at 29.1%, Asia Pacific, the Middle East and Africa at 9.9%, and China at 5.6%. The company develops sequencing and array platforms for genomic analysis, with instruments and consumables such as reagents, flow cells and library preparation kits. Its whole-genome and targeted resequencing kits cover entire genomes, exomes, specific genes and RNA regions. Customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical and biotechnology companies, commercial molecular diagnostic laboratories and consumer genomics firms. Products are sold directly and through life-science distributors, and services include whole-genome sequencing, genotyping, noninvasive prenatal testing and product support. Collaborations with Labcorp on oncology and with Integrated DNA Technologies on somatic oncology research extend its work.
In the fiscal year ended December 2025, revenue reached USD 4.3 billion, down 0.7% from the prior year, and net income was USD 850 million. The company employed 8,600 people, and it was incorporated in 1998 and headquartered in San Diego, California.
Company facts
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Headquarters
- 5200 Illumina Way, 92122, San Diego
- Employees
- 8,600
- Chief executive
- Jacob Thaysen
- Founded
- 1998
- Fiscal year
- January - December
- Listing
- ILMN · NASDAQ
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US4523271090
- Website
- illumina.com
Illumina and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| IlluminaILMN | United States | $29.94B | 8,600 | 19.1% | 34.5 |
| Labcorp HoldingsLH | United States | $30.24B | 71,000 | 11.2% | 30.5 |
| Quest DiagnosticsDGX | United States | $28.85B | 60,000 | 14.9% | 26.1 |
| Mettler-Toledo InternationalMTD | United States | $34.07B | 16,600 | 27.8% | 37.2 |
| NateraNTRA | United States | $41.83B | 6,135 | -8.5% | — |
| IQVIA HoldingsIQV | United States | $42.63B | 95,000 | 13.9% | 31.5 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
